NCT07416812Completed
Targeted Prostate Cancer Screening in Men With BRCA1/2 Mutations
The Identification of Men With a Genteic Predisposition to Prostate Cancer: Targeted Screening in Men at Higer Genetic Risk and Controls Study
Source: ClinicalTrials.gov · Last updated 18 Feb 2026
Brief summary (registry, in English)
This interventional study is a follow-up component of the IMPACT project, which aims to identify men at increased hereditary risk of prostate cancer. The study focuses on men carrying BRCA1 and BRCA2 germline mutations and a control group of non-carriers. Participants are contacted by telephone to determine whether they developed prostate cancer during 2025 and to collect updated personal and family medical history information. The goal of the study is to support targeted prostate cancer screening programs in men at higher genetic risk.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 25 (actual)
- First submitted
- 6 Feb 2026
- Start date
- 29 Mar 2021
- Primary completion date
- 30 Nov 2021
- Lead sponsor
- Institute of Oncology Ljubljana
- Diseases
- Prostate cancer
- NCT number
- NCT07416812
What you commit to
- Study type: Interventional
- Participants enrolled: 25
- From 29 Mar 2021 to the primary completion date, 30 Nov 2021
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of prostate cancer prior to enrollment
Other illness
- Any condition that, in the investigator's opinion, would interfere with study participation or data quality
Other
- Inability to provide informed consent or complete follow-up procedures
Who the study is looking for
- Male participants aged 18 years or older
- BRCA1 or BRCA2 mutation carriers or non-carrier controls enrolled in the IMPACT study
- Eligible for targeted prostate cancer screening and follow-up
- Ability to participate in telephone follow-up interview
- Written informed consent provided
Age in the registry: 18 years to - · Sex: Male · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of Oncology Ljubljana Coordinator of this site? Confirm its status | Ljubljana | Slovenia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.